WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 1, 2008, Pages 113-116

  Stauss, Hans J ^a   Thomas, Sharyn ^a   Cesco Gaspere, Michela ^a   Hart, Daniel P ^a   Xue, Shao An ^a   Holler, Angelika ^a   King, Judy ^a   Wright, Graham ^a   Perro, Mario ^a   Pospori, Constantina ^a   Morris, Emma ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cytotoxic T lymphocytes; Gene therapy; Immunotherapy; T cell receptor; Wilms Tumour Antigen 1

Indexed keywords

HLA A2 ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; WT1 PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL FUNCTION; CELL SPECIFICITY; CLINICAL TRIAL; CLONING; COLON CANCER; DRUG EFFICACY; DRUG SAFETY; GENE CONSTRUCT; GENE EXPRESSION; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; LEUKEMIA; NONHUMAN; NONOBESE DIABETIC MOUSE; OVARY CANCER; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TUMOR VOLUME;

ADOPTIVE TRANSFER; GENES, T-CELL RECEPTOR; HUMANS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; WT1 PROTEINS;

MUS;

EID: 36549023384     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.06.018     Document Type: Article

References (29)

1. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
2. Oka Y., Tsuboi A., Kawakami M., Elisseeva O.A., Nakajima H., et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr. Med. Chem. 13 (2006) 2345-2352
3. Sugiyama H. Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol. Med. 68 (2002) 223-237
4. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100 (2002) 3835-3837
5. Gao L., Bellantuono I., Elsasser A., Marley S.B., Gordon M.Y., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95 (2000) 2198-2203
6. Gao L., Xue S.A., Hasserjian R., Cotter F., Kaeda J., et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75 (2003) 1429-1436
7. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64 (2004) 386-390
8. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163 (1999) 507-513
9. Clay T.M., and Nishimura M.I. Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytes. Methods Mol. Biol. 215 (2003) 227-234
10. Cooper L.J., Kalos M., Lewinsohn D.A., Riddell S.R., and Greenberg P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74 (2000) 8207-8212
11. Fujio K., Misaki Y., Setoguchi K., Morita S., Kawahata K., et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J. Immunol. 165 (2000) 528-532
12. Heemskerk M.H., Hoogeboom M., de Paus R.A., Kester M.G., van der Hoorn M.A., et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102 (2003) 3530-3540
13. Heemskerk M.H., Hoogeboom M., Hagedoorn R., Kester M.G., Willemze R., et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199 (2004) 885-894
14. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., and Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2 (2001) 957-961
15. Morgan R.A., Dudley M.E., Yu Y.Y., Zheng Z., Robbins P.F., et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171 (2003) 3287-3295
16. Morris E.C., Tsallios A., Bendle G.M., Xue S.A., and Stauss H.J. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7934-7939
17. Schaft N., Willemsen R.A., de Vries J., Lankiewicz B., Essers B.W., et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J. Immunol. 170 (2003) 2186-2194
18. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2 (2001) 962-970
19. Tahara H., Fujio K., Araki Y., Setoguchi K., Misaki Y., et al. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J. Immunol. 171 (2003) 2154-2160
20. Xue S.A., Gao L., Hart D., Gillmore R., Qasim W., et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106 (2005) 3062-3067
21. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
22. Call M.E., and Wucherpfennig K.W. The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu. Rev. Immunol. 23 (2005) 101-125
23. Heemskerk M.H., Hagedoorn R.S., van der Hoorn M.A., van der Veken L.T., Hoogeboom M., et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109 (2007) 235-243
24. Sommermeyer D., Neudorfer J., Weinhold M., Leisegang M., Engels B., et al. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36 (2006) 3052-3059
25. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., and Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66 (2006) 8878-8886
26. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67 (2007) 3898-3903
27. Kuball J., Dossett M.L., Wolfl M., Ho W.Y., Voss R.H., et al. Facilitating matched pairing and expression of TCR-chains introduced into human T-cells. Blood (2006)
28. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115 (2005) 1616-1626
29. Cavalieri S., Cazzaniga S., Geuna M., Magnani Z., Bordignon C., et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102 (2003) 497-505